---
title: 'Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous
  gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic
  cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial'
date: '2024-08-19'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39159648/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240820182437&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: A standardised dose-reduction strategy has not been established
  for the widely used gemcitabine plus nab-paclitaxel regimen in patients with metastatic
  pancreatic ductal adenocarcinoma. We aimed to investigate the efficacy and tolerability
  of alternating treatment cycles of nab-paclitaxel-gemcitabine combination therapy
  and gemcitabine alone versus continuous treatment with the nab-paclitaxel-gemcitabine
  ...'
disable_comments: true
---
BACKGROUND: A standardised dose-reduction strategy has not been established for the widely used gemcitabine plus nab-paclitaxel regimen in patients with metastatic pancreatic ductal adenocarcinoma. We aimed to investigate the efficacy and tolerability of alternating treatment cycles of nab-paclitaxel-gemcitabine combination therapy and gemcitabine alone versus continuous treatment with the nab-paclitaxel-gemcitabine ...